NO20060399L - (2S,4S)-4-fluor-1-[4-fluor-beta-(4-fluorfenyl)-L-fenyl alanyl]-2-pyrrolidinkarbonitril p-toluensulfonsyresalt og ikke vannholdige krystallformer av denne - Google Patents
(2S,4S)-4-fluor-1-[4-fluor-beta-(4-fluorfenyl)-L-fenyl alanyl]-2-pyrrolidinkarbonitril p-toluensulfonsyresalt og ikke vannholdige krystallformer av denneInfo
- Publication number
- NO20060399L NO20060399L NO20060399A NO20060399A NO20060399L NO 20060399 L NO20060399 L NO 20060399L NO 20060399 A NO20060399 A NO 20060399A NO 20060399 A NO20060399 A NO 20060399A NO 20060399 L NO20060399 L NO 20060399L
- Authority
- NO
- Norway
- Prior art keywords
- fluoro
- pyrrolidinecarbonitrile
- fluorophenyl
- acid salt
- toluenesulfonic acid
- Prior art date
Links
- MSCWUTTUQLYJFT-QMBKNIKNSA-N (2s,4s)-1-[(2s)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 MSCWUTTUQLYJFT-QMBKNIKNSA-N 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48890203P | 2003-07-21 | 2003-07-21 | |
| PCT/US2004/023263 WO2005009956A1 (en) | 2003-07-21 | 2004-07-19 | (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-l-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060399L true NO20060399L (no) | 2006-02-17 |
Family
ID=34102801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060399A NO20060399L (no) | 2003-07-21 | 2006-01-25 | (2S,4S)-4-fluor-1-[4-fluor-beta-(4-fluorfenyl)-L-fenyl alanyl]-2-pyrrolidinkarbonitril p-toluensulfonsyresalt og ikke vannholdige krystallformer av denne |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7462641B2 (pt) |
| EP (1) | EP1654226B1 (pt) |
| JP (1) | JP2006528187A (pt) |
| KR (1) | KR20060037391A (pt) |
| CN (1) | CN1852893A (pt) |
| AT (1) | ATE411980T1 (pt) |
| AU (1) | AU2004259741A1 (pt) |
| BR (1) | BRPI0412763A (pt) |
| CA (1) | CA2532397A1 (pt) |
| DE (1) | DE602004017325D1 (pt) |
| IL (1) | IL173059A0 (pt) |
| MA (1) | MA27934A1 (pt) |
| MX (1) | MXPA06000725A (pt) |
| NO (1) | NO20060399L (pt) |
| RU (1) | RU2006106429A (pt) |
| WO (1) | WO2005009956A1 (pt) |
| ZA (1) | ZA200600605B (pt) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0510284A (pt) | 2004-05-12 | 2007-10-30 | Pfizer Prod Inc | derivados de prolina e seu uso como inibidores da dipeptidil peptidase iv |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| EP1888562B1 (en) | 2005-04-22 | 2014-06-18 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-iv inhibitors |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| US20100120940A1 (en) | 2007-04-05 | 2010-05-13 | Nippon Shokubai Co., Ltd. | Particulate water-absorbing agent having water-absorbing resin as main component |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| JP5989965B2 (ja) * | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| WO2009114181A2 (en) * | 2008-03-12 | 2009-09-17 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines solid |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| HUE050287T2 (hu) | 2009-02-13 | 2020-11-30 | Boehringer Ingelheim Int | SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2836211B1 (en) | 2012-04-14 | 2019-03-20 | Intra-Cellular Therapies, Inc. | Treatment of PTSD and impulse control disorders |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| PT2968320T (pt) | 2013-03-15 | 2021-01-28 | Intra Cellular Therapies Inc | Compostos orgânicos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| IL321987A (en) | 2013-12-03 | 2025-09-01 | Intra Cellular Therapies Inc | A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders |
| WO2015154025A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN106456638A (zh) | 2014-04-04 | 2017-02-22 | 细胞内治疗公司 | 有机化合物 |
| MX386778B (es) | 2015-03-09 | 2025-03-19 | Intekrin Therapeutics Inc | Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia. |
| CA3011983A1 (en) | 2016-01-26 | 2017-08-03 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines |
| EP3407889B1 (en) | 2016-03-25 | 2021-05-19 | Intra-Cellular Therapies, Inc. | Organic compounds and their use in treating or preventing central nervous system disorders |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| JP2019513143A (ja) | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| JP6997718B2 (ja) | 2016-03-28 | 2022-01-18 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規共結晶 |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018175969A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| WO2018187350A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
| IL272252B2 (en) | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
| KR102899502B1 (ko) | 2017-07-26 | 2025-12-11 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| MX2020007271A (es) | 2017-09-26 | 2020-08-17 | Intra Cellular Therapies Inc | Sales y cristales novedosos. |
| CN109867674A (zh) * | 2017-12-05 | 2019-06-11 | 上海度德医药科技有限公司 | 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型 |
| MX2020009928A (es) | 2018-03-23 | 2021-01-08 | Intra Cellular Therapies Inc | Compuestos organicos. |
| EP3628007B1 (en) | 2018-06-06 | 2023-05-03 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| EP3609891B1 (en) | 2018-06-11 | 2026-02-11 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| WO2020047241A1 (en) | 2018-08-29 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| WO2020047407A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20210052472A (ko) | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| WO2020072796A1 (en) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| BR112022000231A2 (pt) | 2019-07-07 | 2022-02-22 | Intra Cellular Therapies Inc | Novos métodos |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1990469A (zh) * | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
-
2004
- 2004-07-19 WO PCT/US2004/023263 patent/WO2005009956A1/en not_active Ceased
- 2004-07-19 EP EP04778669A patent/EP1654226B1/en not_active Expired - Lifetime
- 2004-07-19 BR BRPI0412763-3A patent/BRPI0412763A/pt not_active Application Discontinuation
- 2004-07-19 DE DE602004017325T patent/DE602004017325D1/de not_active Expired - Fee Related
- 2004-07-19 US US10/565,294 patent/US7462641B2/en not_active Expired - Fee Related
- 2004-07-19 CA CA002532397A patent/CA2532397A1/en not_active Abandoned
- 2004-07-19 AT AT04778669T patent/ATE411980T1/de not_active IP Right Cessation
- 2004-07-19 MX MXPA06000725A patent/MXPA06000725A/es unknown
- 2004-07-19 KR KR1020067001464A patent/KR20060037391A/ko not_active Ceased
- 2004-07-19 RU RU2006106429/04A patent/RU2006106429A/ru not_active Application Discontinuation
- 2004-07-19 CN CNA2004800270931A patent/CN1852893A/zh active Pending
- 2004-07-19 AU AU2004259741A patent/AU2004259741A1/en not_active Abandoned
- 2004-07-19 JP JP2006521180A patent/JP2006528187A/ja active Pending
-
2006
- 2006-01-10 IL IL173059A patent/IL173059A0/en unknown
- 2006-01-20 ZA ZA200600605A patent/ZA200600605B/en unknown
- 2006-01-25 NO NO20060399A patent/NO20060399L/no not_active Application Discontinuation
- 2006-01-27 MA MA28758A patent/MA27934A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005009956A1 (en) | 2005-02-03 |
| ZA200600605B (en) | 2007-05-30 |
| CN1852893A (zh) | 2006-10-25 |
| EP1654226A1 (en) | 2006-05-10 |
| US7462641B2 (en) | 2008-12-09 |
| MA27934A1 (fr) | 2006-06-01 |
| BRPI0412763A (pt) | 2006-09-26 |
| IL173059A0 (en) | 2006-06-11 |
| ATE411980T1 (de) | 2008-11-15 |
| AU2004259741A1 (en) | 2005-02-03 |
| KR20060037391A (ko) | 2006-05-03 |
| JP2006528187A (ja) | 2006-12-14 |
| RU2006106429A (ru) | 2006-08-27 |
| DE602004017325D1 (de) | 2008-12-04 |
| EP1654226B1 (en) | 2008-10-22 |
| US20070066677A1 (en) | 2007-03-22 |
| CA2532397A1 (en) | 2005-02-03 |
| MXPA06000725A (es) | 2006-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060399L (no) | (2S,4S)-4-fluor-1-[4-fluor-beta-(4-fluorfenyl)-L-fenyl alanyl]-2-pyrrolidinkarbonitril p-toluensulfonsyresalt og ikke vannholdige krystallformer av denne | |
| SV2003001144A (es) | FORMAS CRISTALINAS DE LA SAL DE CALCIO DEL ACIDO [R-(R*,R*)]-2-(4-FLUOROFENIL)-ß,ô-DIHIDROXI-5-(1-METILETIL)-3-FENIL-4[(FENILAMINO)CARBONIL]-1H-PIRROL-1-HEPTANOICO (2:1) REF. PC430-01FJT | |
| EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
| EA200301289A1 (ru) | Новые производные пиррола в качестве фармацевтических средств | |
| NO20044221L (no) | Nye forbindelser | |
| PL373645A1 (en) | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors | |
| EA200601552A1 (ru) | Замещенные конденсированные гетероциклические с-гликозиды | |
| EA200702346A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| CY1105994T1 (el) | Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων | |
| DE60218064D1 (de) | Neues peptid mit angiotensinkonvertase hemmender wirkung | |
| DE60320784D1 (de) | Stände zur modulierung des knochenwachstums | |
| NO20050019L (no) | Polytylenglykolaldehyd-derivater | |
| NO20055741D0 (no) | Nye kjemiske forbindelser | |
| DK1427286T3 (da) | Fremgangsmåde til udtynding af frugt | |
| ATE549024T1 (de) | Chinazolin-kaliumkanalhemmer | |
| ATE417545T1 (de) | Katheterkopf | |
| DE60327936D1 (de) | Modulatoren von ship-1 | |
| EA201000566A1 (ru) | Гетероциклические сетр ингибиторы | |
| EA200501557A1 (ru) | Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла | |
| ATE548350T1 (de) | N-arylpiperidin-substituierte biphenylcarbonsäureamide als inhibitoren von apolipoprotein b | |
| DE602004018162D1 (de) | hERG1-KANAL-ÖFFNER ZUR BEHANDLUNG VON HERZARRYTHMIEN | |
| DE59910956D1 (de) | Medizinische Verwendung von Mechanismus-orientierten Inhibitoren der Dipeptidylpeptidase I | |
| GEP20063936B (en) | New anhydrous crystalline forms of gabapentin | |
| NO20062022L (no) | 1-(kinolinamino)- og 1-(isokinolinamino)-substituerte pentan-2-oler, fremgangsmate for fremstilling av disse og anvendelse av den som antiinflammatoriske midler | |
| BR0311590A (pt) | Agonistas de brs-3 não-peptìdicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |